Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies
| Autor: | Nataliya Chernyukhin, Tianling Chen, Stephen E. Spurgeon, Paul M. Barr, Ahmed Hamdy, Raquel Izumi, Jeff Porter Sharman, Mark Roschewski, Jason M. Melear, Elena Bibikova, Ming Yin, J. Greg Slatter, Stephen D. Smith, Susan O'Brien |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research biology business.industry 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Oncology hemic and lymphatic diseases 030220 oncology & carcinogenesis Relapsed refractory Cancer research medicine biology.protein bacteria Acalabrutinib Bruton's tyrosine kinase In patient business B cell |
| Zdroj: | Journal of Clinical Oncology. 36:7518-7518 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 7518Background: Acalabrutinib, a selective, covalent inhibitor of Bruton tyrosine kinase (BTK), was evaluated in combination with the PI3Kδ inhibitor ACP-319 in pts with R/R B-cell malignancies. Me... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|